Compare CVLG & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVLG | RIGL |
|---|---|---|
| Founded | 1986 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 587.9M | 537.6M |
| IPO Year | 1994 | 2000 |
| Metric | CVLG | RIGL |
|---|---|---|
| Price | $22.63 | $44.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $36.00 | ★ $43.20 |
| AVG Volume (30 Days) | 137.8K | ★ 529.1K |
| Earning Date | 01-22-2026 | 11-04-2025 |
| Dividend Yield | ★ 1.23% | N/A |
| EPS Growth | N/A | ★ 2698.26 |
| EPS | 1.18 | ★ 6.20 |
| Revenue | ★ $1,146,429,000.00 | $282,076,000.00 |
| Revenue This Year | $4.11 | $65.53 |
| Revenue Next Year | $5.94 | $0.22 |
| P/E Ratio | $19.37 | ★ $7.09 |
| Revenue Growth | 1.62 | ★ 79.13 |
| 52 Week Low | $17.46 | $14.63 |
| 52 Week High | $29.47 | $52.24 |
| Indicator | CVLG | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 59.22 | 55.88 |
| Support Level | $22.15 | $40.52 |
| Resistance Level | $23.09 | $43.58 |
| Average True Range (ATR) | 0.76 | 2.42 |
| MACD | -0.01 | -0.33 |
| Stochastic Oscillator | 53.36 | 48.65 |
Covenant Logistics Group Inc together with its wholly-owned subsidiaries offers truckload transportation and freight brokerage services to customers throughout the continental United States. The company's reportable segments include Expedited, Dedicated Services, Managed Freight and Warehousing. Expedited segment provides truckload services to customers with high service freight and delivery standards. Dedicated segment provides customers with committed truckload capacity over contracted periods with the goal of three to five years in length. Managed Freight segment includes brokerage services and TMS. Warehousing segment provides day-to-day warehouse management services to customers who have chosen to outsource this function. Majority of revenue is generated from expedited segment.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.